6,678 trials
Cost Sharing, Acute Coronary Syndrome
Primary: Kaplan-Meier Cumulative Incidence Rate of Major Adverse Cardiovascular Events — 10.17; 10.93 Percentage of Participants — p=0.3503
Relapsing Remitting Multiple Sclerosis
Primary: Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA — 212.26; 404.31; 1.15; 1.06 pg/ml — p=0.000
Chronic Weight Management
Primary: Percentage of Participants Reporting at Least One of Nine Adverse Events (AEs) of Main Interests That May Related to Serotonergic Reaction — 37.2; 42.3; 40.5 percentage…
Shoulder Hand Syndrome · Complex Regional Pain Syndromes
Primary: Number of Participants Demonstrating Tolerability of Suprascapular and Median Nerve Blocks — 5 Participants
Aesthetics
Primary: Percentage of Subjects With Improvement in Global Facial Aesthetic Appearance — 66.7; 93.5 percentage of subjects
Nicotine Dependence · Smoking Cessation
Primary: Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days — 12; 7 Participants
Polycystic Ovary Syndrome · Infertility
Primary: Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level — 15; 27 Participants — p=0.007
Breast Cancer
Primary: Number of Participants With Complete Response (CR) — 161 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Intensity of Breathlessness Measured Using the Modified Borg Scale at the End of the 3 Minute (Min) Constant Speed Shuttle Test After 6 Weeks of…
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — -0.042; 0.006; 0.033; 0.022 Liters
Plaque Psoriasis
Primary: Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16 — 74.7; 71.3; 61.7; 70.8 Percentage of participants
Sub-acute Back Pain
Primary: Number of Participants With 20% Reduction in Pain on the NRS Pain Intensity Scale — 5; 15; 21 Participants — p=1.0
Testosterone Deficiency · Hypogonadism, Male
Primary: Change in Levels of Serum Total Testosterone Concentration — NA; 1043.6; NA; 785.7 ng/dl
Crohn's Disease
Primary: Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) — 75.0; 75.0 percentage…
Fibromyalgia
Primary: Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment. — 77.2; 126.7; 81.0 pg/mL — p=< 0.01